您当前所在的位置:首页 > 产品中心 > 产品详细信息
23031-25-6 分子结构
点击图片或这里关闭

5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol

ChemBase编号:749
分子式:C12H19NO3
平均质量:225.28416
单一同位素质量:225.13649347
SMILES和InChIs

SMILES:
OC(CNC(C)(C)C)c1cc(O)cc(O)c1
Canonical SMILES:
OC(c1cc(O)cc(c1)O)CNC(C)(C)C
InChI:
InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
InChIKey:
XWTYSIMOBUGWOL-UHFFFAOYSA-N

引用这个纪录

CBID:749 http://www.chembase.cn/molecule-749.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
IUPAC传统名
terbutaline
商标名
Brethaire
Brethine
Brican
Bricanyl
Bricar
Bricaril
Bricyn
别名
2-tert-Butylamino-1-(3,5-dihydroxyphenyl)ethanol Hemisulfate
Brethaire
Brethine
Butalire
Monovent
Terbasmin
Terbul
Terbutaline Hemisulfate Salt
5-(2-(tert-ButylaMino)-1-hydroxyethyl)benzene-1,3-diol
Terbutalina [Dcit]
Terbutaline Sulfate
Terbutalino [INN-Spanish]
Terbutalinum [INN-Latin]
Terbutalin
Terbutaline
CAS号
23031-25-6
23031-32-5
PubChem SID
160964212
46506887
PubChem CID
5403

数据来源

数据来源

所有数据来源 商品来源 非商品来源

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 8.85872  质子受体
质子供体 LogD (pH = 5.5) -1.8226097 
LogD (pH = 7.4) -0.726437  Log P 0.44103742 
摩尔折射率 63.0359 cm3 极化性 24.725668 Å3
极化表面积 72.72 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 0.55  LOG S -1.59 
溶解度 5.84e+00 g/l 

分子性质

分子性质

理化性质 安全信息 产品相关信息 生物活性(PubChem)
溶解度
213 mg/mL expand 查看数据来源
DMSO expand 查看数据来源
Ethanol expand 查看数据来源
Methanol expand 查看数据来源
外观
White to Off-White Solid expand 查看数据来源
熔点
246-248°C expand 查看数据来源
疏水性(logP)
1.4 expand 查看数据来源
保存条件
-20°C Freezer expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
纯度
98% expand 查看数据来源
质检报告
下载链接 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank TRC TRC
DrugBank -  DB00871 external link
Item Information
Drug Groups approved
Description A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [PubChem]
Indication For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.
Pharmacology Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation.
Toxicity Terbutaline Sulfate: Oral LD50(rat) = 8.7 g/kg; Oral LD50(mouse) = 205 mg/kg; Oral LD50(dog) = 1.5 g/kg; IP LD50(rat)= 220 mg/kg ; IP LD50(mouse) = 130 mg/kg; Oral LD50(rabbit) = >8 g/kg; IV LD50(mouse) = 36 mg/kg; IV LD50(dog) = 116 mg/kg; IV LD50(rabbit) = 110 mg/kg
Affected Organisms
Humans and other mammals
Absorption Approximately 30-50% if administered orally and well absorbed subcutaneously.
Half Life 5.5-5.9 hours
Elimination About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination
Clearance * 311 +/- 112 mL/min
References
Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. [Pubmed]
Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [Pubmed]
Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com
Toronto Research Chemicals -  T109750 external link
A B-Adrenergic receptor agonist. A Bronchodilator.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. Pubmed
  • Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. Pubmed
  • Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. Pubmed
  • Akhtar, S., et al.: J. Vet. Pharmacol. Ther., 21, 388 (1998)
  • Kasprowicz, D.J., et al.: J. Immunol., 165, 680 (2000)
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle